clinical trial · NCT07142642
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
Amgen·phase1·completed·n = 20
Healthy VolunteersTeprotumumabPlacebo
brief summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
started
Aug 26, 2025
primary completion
Nov 22, 2025
completion
Jan 15, 2026
last updated
Feb 27, 2026
official title
A Phase 1, Randomized, Placebo-controlled, Double-blind, Single-dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol